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Rhodococcus-equi speciﬁc hyperimmune plasma
decreased rhodococcal pneumonia severity in
newborn foals after experimental infection
M.G. Sanz*, A. Loynachan, D.W. Horohov
Maxwell H. Gluck Equine Research Center (Sanz, Horohov),
Veterinary Diagnostic Laboratory (Loynachan) Department of
Veterinary Science, University of Kentucky, Lexington, KY
40546-0099Rhodococcus equi is the most common cause of pneumonia in
young foals. As a vaccine is not available, farms with an endemic
problem rely in the use of R. equi speciﬁc hyperimmune plasma
(HIP), although the efﬁcacy of this practice remains uncertain. The
objective of this study was to evaluate the ability of a commer-
cially available HIP to prevent clinical rhodococcal pneumonia in
neonatal foals after experimental challenge. Nine foals were given
intravenous HIP after birth while 9 remained as controls. Within
the ﬁrst week of life, all foals received 103cfu/foal of pathogenic R.
equi intratracheally as previously described (Sanz et al 2013).
Thereafter, foals were monitored for 8 weeks and samples were
collected during that period as described before (Sanz et al 2013).
VapA-speciﬁc IgG and IgG subclasses in serum and in bron-
choalveolar lavage ﬂuid (BALF) were evaluated using ELISA (Sanz
et al 2014). One foal in the HIP group and 4 in the control group
developed clinical pneumonia; however, the power of the study
was too low to detect a statistical signiﬁcant effect of treatment.
HIP foals had signiﬁcantly lower weekly ultrasonographic scores
(p<0.05, Figure 1), lower white blood cell counts (p¼0.03),
platelet counts (p¼0.01) and ﬁbrinogen concentration (p¼0.01)
than controls. Serum VapA-speciﬁc IgG, IgGa and IgGb were
signiﬁcantly higher in HIP foals and IgGa and IgG(T) signiﬁcantly
increased (p<0.001) over time only in control foals. VapA-speciﬁc
IgG (p¼0.02) and IgGb (p¼0.04) were signiﬁcantly higher in BALF
of HIP foals. In this study, HIP administration decreased severity of
pneumonia, which reduced the need for antimicrobial treatment.
Antibodies present in HIP transferred to BALF of foals shortly afterFigure 1. Thoracic ultrasound score (diameter, cm) of neonatal foals
experimentally challenged with R. equi after administration of HIP (black) or
nothing (gray). The horizontal line within the box represents the median
and the ends of the box the 75th and 25th quantiles respectively. The asterisk
(*) indicates that values signiﬁcantly differ (p<0.05) from the pre-challenge
(w1) value for each group. The hash (#) indicates that values signiﬁcantly
(p<0.05) differ between groups at a given time point.HIP administration. VapA-speciﬁc IgG(T), which increases with R.
equi infection, was only elevated in control foals. In conclusion,
while infection after challenge was not prevented by R. equi-
speciﬁc hyperimmune plasma (HIP) administration, severity of
clinical pneumonia decreased.References
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Variation of anti-Rhodococcus equi VapA speciﬁc IgGs
among eleven different lots of one commercially
available Rhodococcus equi speciﬁc hyperimmune
plasma product
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Lexington, KY 40511Rhodococcus equi, a gram-positive facultative intracellular
pathogen, is the most common cause of pneumonia in foals
between 3 weeks and 5 months of age. To date, there is no
vaccine available, and mass treatment of foals with antibiotics
may incur in serious long-term effects and is strongly discour-
aged. Therefore, on farms with enzootic rhodococcal pneu-
monia, prophylaxis measures rely greatly on the administration
of R. equi speciﬁc hyperimmune plasma (HIP). The efﬁcacy of R.
equi HIP in controlling disease due to either natural or induced
infection has been historically controversial. Variability in
plasma products may have played an important role. Recently,
four commercial R equi HIP products were evaluated for their
concentrations of Vap-A speciﬁc immunoglobulin G (IgG) and
IgG subclasses. Marked variation was observed between
different products, and different lots from the same product,
which may have important clinical and ﬁnancial consequences.
In order to further investigate the amount of variation in a
commercially available plasma product, and its relation with
speciﬁc R. equi IgG in the recipient foals, a foal population from a
local farm that routinely receives R. equi speciﬁc HIP due to
enzootic R. equi pneumonia, was selected. Exclusion criteria for
the foals were documented failure of passive transfer, and clin-
ical disease other than pneumonia. All newborn foals received 1
liter of intravenous R. equi HIP1 within 24 hours after being born.
HIP samples (n ¼ )were collected at administration time. Serum
samples were collected from all healthy foals (n ¼ ) and their
respective dams (n ¼ ) within 24 and 48 hours after HIP
administration. All samples were archived in -20C for batch
analysis with previously validated ELISA for equine anti-VapA
total IgG and IgG(a), IgG(b), and IgG(t). Eleven different HIP lots
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of all anti-VapA speciﬁc IgG concentrations (Table 1). When anti-
VapA speciﬁc IgG concentrations were compared between the
dam’s serum, R. equi HIP, and foal’s serum, either weak positive
or negative linear correlations were observed (-0.15 < r < 0.20),
with the exception of IgG(t), which showed a moderate positive
linear correlation between R. equi speciﬁc HIP, and foal’s serum
(r ¼ 0.71). Our results revealed an even greater variation in anti-
VapA speciﬁc IgG concentrations within and among the different
lots of the selected R. equi HIP product, than previously reported.
This ﬁnding may corroborate in explaining historical disparities
regarding R. equi speciﬁc HIP efﬁcacy in preventing R. equi
pneumonia in foals. The lack of a positive correlation between
the anti-VapA speciﬁc IgG concentrations between the dams,
HIP and the recipient foals is not fully understood. However,
possible explanations include suboptimal time sampling of the
dams, low anti-VapA speciﬁc IgG concentrations in adult horses,
and unknown antibody kinetics of the anti-VapA speciﬁc IgGs in
the recipient foal. Recently, it has been reported that after
intravenous administration of R. equi HIP, the concentrations of
anti-VapA speciﬁc IgGs in the bronchoalveolar ﬂuid increases,
suggesting compartmentalization of these antibodies outside
the systemic circulation. The moderate positive correlation
observed between the concentrations of IgG(t) between the R.
equi HIP and the recipient foals was likely due to its high con-
centration in the HIP product. Serial measurements of the foal’s
serum concentrations of anti-VapA speciﬁc IgGs is warranted in
order to evaluate their relationship with clinical disease, and
therefore the efﬁcacy of this commercially available R. equi HIP
in preventing naturally acquired pneumonia in foals.Table 1
Intra- and inter-lot coefﬁcient of variation (CV) of anti-VapA speciﬁc IgG
concentrations in different lots of R. equi HIP1.
CV(%)
Lot # IgG total IgGa IgGb IgGt
1 49.39 51.74 54.50 32.79
2 45.02 57.73 32.89 28.15
3 58.52 63.38 55.71 39.15
4 57.81 65.87 59.07 58.03
5* - - - -
6 39.18 55.54 46.33 47.53
7 60.43 61.40 59.22 58.09
8 70.83 91.88 79.37 31.83
9 51.96 56.79 71.16 52.33
10* - - - -
11* - - - -
All lots 60.88 62.70 87.63 90.97* Only one HIP bag was sampled.
Reference
[1] ImmunoGlo, MgBiologics, Aimes, Iowa, USA.
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Bronchopneumonia caused by Rhodococcus equi is an important
and often debilitating disease of young horses throughout the
world. Advances in diagnostic methods for the early detection
of lung lesions, such as ultrasonographic imaging, have been
associated with an increase in the use of antimicrobial agents
for the treatment of this disease. Concurrent with this increased
usage, reports of antimicrobial resistance in R. equi have
become more common in recent years. The aim of this study
was to determine the level of resistance to three commonly
prescribed antimicrobial agents in 97 virulent Rhodococcus equi
isolates collected from infected foals between 1991 and 2014.
The second objective was to determine the utility of a novel
assay for determining the minimum inhibitory concentration
(MIC) of R. equi isolates with a single agent, or when rifampicin
and erythromycin were combined. Three cohorts of virulent
Rhodococcus equi isolates were included in the study. Cohort 1
contained 29 isolates collected from clinical cases between
1991 and 1998 and Cohort 2 consisted of 12 recent isolates
collected between 2011 and 2014. Fifty six isolates from clini-
cally affected foals undergoing antimicrobial therapy in 2006 -
2007 on an endemically infected farm formed Cohort 3. The
MICs for rifampicin, erythromycin and neomycin were deter-
mined for all of the isolates using a novel microtitre assay.
Rifampicin resistance was detected in 3 of the 12 isolates in
Cohort 2. The MIC was 64 mg/mL for two of the isolates and 16
mg/mL for the third, well above the threshold of 8 mg/mL that
deﬁnes resistance to this agent. All isolates collected prior to
2013 had MICs less than 0.125 mg/mL (limit of detection). None
of the isolates were resistant to either neomycin or erythro-
mycin, with MIC values ranging from 0.25 - 2 mg/mL for
neomycin and 0.125 - 1 mg/mL for erythromycin. When rifam-
picin and erythromycin were tested in combination, the MIC
value for the isolates resistant to rifampicin were lower,
compared to exposure to rifampicin alone. This is the ﬁrst
report of rifampicin resistance in virulent R. equi isolated from
Australian foals. Sanger sequencing of a portion of the RNA
polymerase b subunit was conducted to further characterise the
resistant isolates from Cohort 2 [1], [2]. The current therapeutic
success of the macrolide - rifampicin combination regimen is
thought to rely on the synergistic action of these two agents in
vivo. It is not clear from these results whether the rifampicin
resistance we have detected has any signiﬁcant impact on
synergy in vivo.References
[1] Fines et al. (2001) J. Clin Micro 39(8): 2784-7.
[2] Zaczek et al. (2009) BMC Micro 9:10.
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